Susan Galbraith on Next Generation Oral SERD AZD9833 #AACR2020

Susan Galbraith on Next Generation Oral SERD AZD9833 #AACR2020

Cancer-News

2 months
14 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Susan Galbraith, Senior Vice President and Head of Research and Early Development, Oncology R&D discusses preclinical pharmacokinetic and metabolic characterization of the next generation oral SERD AZD9833. AZD9833 is a best in class profile, next generation oral selective estrogen receptor degrader (SERD) with an established pharmacokinetic profile in the clinic – specifically, AZD9833 is a full antagonist and complete degrader of estrogen receptor in all preclinical cell line models tested.
Up Next Autoplay